SCHEMBL4720736

SCHEMBL4720736

Cc1cc(C)c(-c2cc(Nc3cccc4cnccc34)ncn2)c(C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.47
MAPT P10636 5/20 0.47
KDM4E B2RXH2 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
KMT2A Q03164 4/20 0.47
MEN1 O00255 2/20 0.44
KDR P35968 4/20 0.43
CCR4 P51679 1/20 0.41
PDE4B Q07343 1/20 0.39
NR3C1 P04150 1/20 0.39
INSR P06213 1/20 0.39
LCK P06239 1/20 0.39
LYN P07948 1/20 0.39
SRC P12931 1/20 0.39
TRPV1 Q8NER1 3/20 0.39
LMNA P02545 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
ROCK2 O75116 1/20 0.38
ROCK1 Q13464 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4718686 0.84 ALDH1A1 (0.48) ALDH1A1MAPTKDM4ESMN1; SMN2KMT2A
SCHEMBL4718684 0.82 CCR4 (0.47) ALDH1A1MAPTKDM4ESMN1; SMN2KMT2A
SCHEMBL4716052 0.81 PDE4B (0.51) ALDH1A1MAPTKDM4ESMN1; SMN2KMT2A
SCHEMBL4719637 0.81 TRPV1 (0.48) ALDH1A1MAPTKDM4ESMN1; SMN2KMT2A
SCHEMBL4717106 0.81 TRPV1 (0.43) ALDH1A1MAPTKDM4ESMN1; SMN2KMT2A
SCHEMBL4716399 0.80 KDR (0.47) ALDH1A1KDRCCR4PDE4BTRPV1
SCHEMBL4718692 0.79 TRPV1 (0.49) ALDH1A1MAPTKDM4EKDRCCR4
SCHEMBL4718504 0.78 TRPV1 (0.59) ALDH1A1MAPTKDM4ESMN1; SMN2KMT2A
SCHEMBL4716401 0.78 TRPV1 (0.48) ALDH1A1MAPTKDM4ESMN1; SMN2KDR
SCHEMBL4715609 0.78 ACP1 (0.52) ALDH1A1MAPTTRPV1LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442701-B2 Amino-heterocycles as VR-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2008-10-28 US disclosed
EP-1562934-B1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME (GB) 2008-03-26 EP disclosed
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2006-02-23 US disclosed
EP-1562934-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2005-08-17 EP disclosed
WO-2004046133-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain OPRL1, CNR1, GPR6 ALDH1A1 2473/4885MAPT 4864/4885KDM4E 4502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.